At Cedar, we believe in the vision that population health and welfare are enhanced by the development and diffusion of innovative healthcare technologies.
To promote this vision, we conduct evidence-based research on the comparative value of health care technologies. For the past two decades, our research has paved the way for breakthrough drugs, devices, and diagnostics to play effective roles in various health care settings.
Our leadership has a unique blend of experience that combines medical and academic training with a pragmatic understanding of challenges of research, and best practices for innovation adoption. Success hinges on a collaborative model, which we find includes payers, providers, key opinion leaders, and medical policy organizations.
Prior economic analysis predicted that a 12-gene assay would improve patient outcomes and lower medical costs for individuals with stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer. A group of researchers, including members of the Mayo Clinic and Cedar Associates, assessed the validity of this prediction by comparing clinicians’ adjuvant chemotherapy (aCT) recommendations before and after knowing the results of the 12-gene assay. Analysis of the data, collected from 17 Mayo Clinic cancer research sites, confirmed that use of the 12-gene assay reduced direct medical costs and improved patients’ wellbeing.